Examination on an effect of continuous intake of a test food product on improving cognitive function in young adults.

Examination on an effect of continuous intake of a test food product on improving cognitive function in young adults. - Examination on an effect of continuous intake of a test food product on improving cognitive function in young adults.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030859

Enrollment

Registered

2018-01-18

Start date

2018-01-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy subjects

Interventions

2-week intake of the test food 2-week intake of the placebo food

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Age: 25 and over, below35 2)Sex: Males and females with Japanese nationality 3)Those who are able to take 9 capsules a day for 2 weeks 4)Non-smoker 5)Workers (excluding students)

Exclusion criteria

Exclusion criteria: 1)Currently in treatment with medication or seeing a doctor for treatment 2)Previous history of hepatic disorder or severe disorder related to kidney, endocrine, cardiovascular system, gastro-intestine, lung, blood, or metabolism, or currently presence of complications 3)Previous history of drug allergy or food allergy 4)Regular intake of a food product or supplements with a possible influence on cognitive function 5)Regular intake of drug with a possible influence on cognitive function 6)Extreme faddiness 7)Extremely irregular lifestyle such as a dietary pattern and a sleeping pattern 8)Suspicion of insomnia 9)Presence or previous history of mental disorder (depression, etc.) 10)Presence or previous history of alcoholism 11)Current participation in another clinical trial or participation in another clinical trial within the last three months 12)Irregular work hours such as working on night shift 13)Determined by the investigator to be unsuitable for enrollment in this study

Design outcomes

Primary

Measure	Time frame
Cognitrax, Uchida-Kraepelin test, VAS	—

Secondary

Measure	Time frame
Hematologic test, blood biochemical test, vital signs	—

Countries

Japan

Contacts

Public ContactOchitani Daisuke

HUMA R&D CORP Clinical Development Division

ochitani@huma-c.co.jp81-3-3431-1260

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026